WO2012078470A3 - Methods of small molecule directed regeneration from pluripotent stem cells - Google Patents

Methods of small molecule directed regeneration from pluripotent stem cells Download PDF

Info

Publication number
WO2012078470A3
WO2012078470A3 PCT/US2011/063101 US2011063101W WO2012078470A3 WO 2012078470 A3 WO2012078470 A3 WO 2012078470A3 US 2011063101 W US2011063101 W US 2011063101W WO 2012078470 A3 WO2012078470 A3 WO 2012078470A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
human stem
pluripotent
small molecule
clinically
Prior art date
Application number
PCT/US2011/063101
Other languages
French (fr)
Other versions
WO2012078470A2 (en
Inventor
Xuejun H. Parsons
Original Assignee
Parsons Xuejun H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parsons Xuejun H filed Critical Parsons Xuejun H
Priority to AU2011338711A priority Critical patent/AU2011338711A1/en
Priority to CA2819675A priority patent/CA2819675A1/en
Publication of WO2012078470A2 publication Critical patent/WO2012078470A2/en
Publication of WO2012078470A3 publication Critical patent/WO2012078470A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)

Abstract

The disclosure is based on the discovery that pluripotent human stem cells maintained under the defined culture conditions can be uniformly converted into a specific lineage by small molecule induction. Retinoic acid induces the specification of neuroectoderm direct from the pluripotent state of human stem cells and triggers progression to neuronal progenitors and neurons efficiently. Similarly, nicotinamide induces the specification of cardiomesoderm direct from the pluripotent state of human stem cells and triggers progression to cardiac precursors and cardiomyocytes efficiently. This technology provides a large supply of clinically-suitable human neuronal or cardiac therapeutic products for CNS or myocardium repair. The disclosure enables well-controlled efficient induction of pluripotent human stem cells exclusively to a specific clinically-relevant lineage for tissue and organ engineering and regeneration, cell-based therapy, and drug discovery.
PCT/US2011/063101 2010-12-06 2011-12-02 Methods of small molecule directed regeneration from pluripotent stem cells WO2012078470A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2011338711A AU2011338711A1 (en) 2010-12-06 2011-12-02 Methods of small molecule directed regeneration from pluripotent stem cells
CA2819675A CA2819675A1 (en) 2010-12-06 2011-12-02 Methods of small molecule directed regeneration from pluripotent stem cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45896510P 2010-12-06 2010-12-06
US61/458,965 2010-12-06
US13/306,114 2011-11-29
US13/306,114 US8716017B2 (en) 2010-12-06 2011-11-29 Technologies, methods, and products of small molecule directed tissue and organ regeneration from human pluripotent stem cells

Publications (2)

Publication Number Publication Date
WO2012078470A2 WO2012078470A2 (en) 2012-06-14
WO2012078470A3 true WO2012078470A3 (en) 2014-04-10

Family

ID=46207658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063101 WO2012078470A2 (en) 2010-12-06 2011-12-02 Methods of small molecule directed regeneration from pluripotent stem cells

Country Status (4)

Country Link
US (3) US8716017B2 (en)
AU (1) AU2011338711A1 (en)
CA (1) CA2819675A1 (en)
WO (1) WO2012078470A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
US8716017B2 (en) 2010-12-06 2014-05-06 San Diego Regenerative Medicine Institute Technologies, methods, and products of small molecule directed tissue and organ regeneration from human pluripotent stem cells
CN106939299B (en) * 2017-02-04 2022-11-15 滨州医学院 Preparation method and application of microRNA (ribonucleic acid) reprogramming somatic cell as neural stem cell
CN107858331B (en) * 2017-11-02 2021-01-15 北京全式金生物技术有限公司 Method for inducing differentiation of human pluripotent stem cells into spinal cord motor nerve precursor cells
EP3818158A1 (en) * 2018-07-02 2021-05-12 Shi-Lung Lin In-vitro induction of adult stem cell expansion and derivation
CN109674809B (en) * 2018-12-27 2022-08-09 吉林大学 Composition containing miR-124-3P and application thereof in medicine for inducing neuron formation
US20230242873A1 (en) * 2020-05-13 2023-08-03 Figene, Llc Fibroblast based therapy for treatment of parkinson's disease
CN112813023A (en) * 2021-02-26 2021-05-18 澳门大学 Method and medicament for inducing stem cells to differentiate towards myocardial cells and passaging and purifying myocardial cells

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292401A1 (en) * 2006-06-20 2007-12-20 Harmon Alexander M Soft tissue repair and regeneration using stem cell products
US20090263360A1 (en) * 2004-10-05 2009-10-22 The University Of Georgia Research Foundation Neuronal progenitors from feeder-free human embryonic stem cell culture
US20100034785A1 (en) * 2006-11-09 2010-02-11 Roger Pedersen Differentiation of Pluripotent Cells into Primary Germ Layer Progenitors
US20100130574A1 (en) * 2008-11-26 2010-05-27 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling
US20100184033A1 (en) * 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
US20100184032A1 (en) * 2006-12-04 2010-07-22 The Johns Hopkins University Stem-Progenitor Cell Specific Micro-Ribonucleic Acids and Uses Thereof
US20100221829A1 (en) * 2005-08-29 2010-09-02 Technion Research & Development Foundation Ltd. Media for culturing stem cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233446A1 (en) 2003-12-31 2005-10-20 Parsons Xuejun H Defined media for stem cell culture
US8716017B2 (en) 2010-12-06 2014-05-06 San Diego Regenerative Medicine Institute Technologies, methods, and products of small molecule directed tissue and organ regeneration from human pluripotent stem cells

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090263360A1 (en) * 2004-10-05 2009-10-22 The University Of Georgia Research Foundation Neuronal progenitors from feeder-free human embryonic stem cell culture
US20100221829A1 (en) * 2005-08-29 2010-09-02 Technion Research & Development Foundation Ltd. Media for culturing stem cells
US20070292401A1 (en) * 2006-06-20 2007-12-20 Harmon Alexander M Soft tissue repair and regeneration using stem cell products
US20100034785A1 (en) * 2006-11-09 2010-02-11 Roger Pedersen Differentiation of Pluripotent Cells into Primary Germ Layer Progenitors
US20100184032A1 (en) * 2006-12-04 2010-07-22 The Johns Hopkins University Stem-Progenitor Cell Specific Micro-Ribonucleic Acids and Uses Thereof
US20100184033A1 (en) * 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
US20100130574A1 (en) * 2008-11-26 2010-05-27 President And Fellows Of Harvard College Neurodegenerative diseases and methods of modeling

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHUNG ET AL.: "Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons.", EUR J NEUROSCI., vol. 16, no. 10, 2002, pages 1829 - 38 *
DUESTER: "Retinoic Acid Synthesis and Signaling during Early Organogenesis.", CELL., vol. 134, no. 6, 2008, pages 921 - 31, XP055092322, doi:10.1016/j.cell.2008.09.002 *
GREGOIRE ET AL.: "Histone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2.", MOL CELL BIO., vol. 27, no. 4, 2007, pages 280 - 95 *
SAMORAJSKI ET AL.: "THE FINE STRUCTURE OF LIPOFUSCIN AGE PIGMENT IN THE I NERVOUS SYSTEM OF AGED MICE.", J CELL BIOL., vol. 26, no. 3, 1965, pages 779 - 95 *
TROUNSON: "The Production and Directed Differentiation of Human Embryonic Stem Cells.", ENDOCR REV., vol. 27, no. 2, 2006, pages 208 - 19, XP009075595 *
VOLAKAKIS ET AL.: "Characterization of the Nurr1 ligand-binding domain co-activator interaction surface.", J MOL ENDOCRINOL., vol. 37, no. 2, 2006, pages 317 - 26 *
WIKIPEDIA_FGF: "Fibroblast growth factor receptor", 6 April 2012 (2012-04-06), Retrieved from the Internet <URL:http://en.wikipedia.orglwiki/Fibroblast_growthfactorreceptor> [retrieved on 20120512] *
WIKIPEDIA_RA, RETINOIC ACID RECEPTOR, 10 December 2011 (2011-12-10), Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Retinoic_acid_receptor> [retrieved on 20120512] *
WIKIPEDIA_RETINOID, RETINOID, 26 April 2012 (2012-04-26), Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Retinoid> [retrieved on 20120514] *
WIKIPEDIA_ROD_CELL, ROD CELL, 26 April 2012 (2012-04-26), Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Rod_cell> [retrieved on 20120514] *
WIKIPEDIA_SHH, SONIC HEDGEHOG, 2 May 2012 (2012-05-02), Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Sonic_hedgehog> [retrieved on 20120515] *
WU ET AL.: "Discovery of sonic hedgehog expression in postnatal growth plate chondrocytes: differential regulation of sonic and Indian hedgehog by retinoic acid.", J CELL BIOCHEM., vol. 87, no. 2, 2002, pages 173 - 87 *

Also Published As

Publication number Publication date
US20140193380A1 (en) 2014-07-10
US20120301437A1 (en) 2012-11-29
WO2012078470A2 (en) 2012-06-14
US8716017B2 (en) 2014-05-06
US20160115446A1 (en) 2016-04-28
US9428731B2 (en) 2016-08-30
CA2819675A1 (en) 2012-06-14
AU2011338711A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
WO2012078470A3 (en) Methods of small molecule directed regeneration from pluripotent stem cells
WO2011149762A3 (en) Method of nociceptor differentiation of human embryonic stem cells and uses thereof
MY151979A (en) Method for producing mesenchymal stem cells from human pluripotent stem cells, and mesenchymal stem cells produced by same
BR112014010776A8 (en) dopaminergic (da) neurons for graft
PH12016500783A1 (en) Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
MY173219A (en) Culture method to obtain and maintain a pure or proliferated population of mammalian neural stem cells and/or neural/progenitor cells that are prone to differentiate into oligodendrocyte-lineage cells in vitro
WO2016061464A8 (en) In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
WO2012047733A3 (en) Treatment of acne by conditioned media
WO2015035136A3 (en) Delivery system for functional nucleases
IL307568A (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
BR112014027783A2 (en) differentiation of human embryonic stem cells into pancreatic endoderm
BR112014015342A2 (en) induced pluripotent stem cells from cells derived from human umbilical cord tissue
EP2504425A4 (en) Differentiation of human embryonic and induced pluripotents stem cells
WO2012092049A8 (en) Brown adipocyte modification
EP2581442A4 (en) Process for production of hematopoietic stem cell
WO2011043629A3 (en) Method of inducing high activity of human adipose stem cell and medium therefor
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2014072720A3 (en) Cell differentiation
BR112014015277A2 (en) induced pluripotent stem cells prepared from human kidney derived cells
WO2013188407A3 (en) In vitro differentiation of motor neuron progenitors from human induced pluripotent stem cells and cryopreservation
WO2014144731A3 (en) Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
WO2013176538A3 (en) Tenogenic medium for mesenchymal stem cells differentation into tenogenic lineage
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
Parsons Exploring future cardiovascular medicine: heart precursors directed from human embryonic stem cells for myocardium regeneration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11846998

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2819675

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011338711

Country of ref document: AU

Date of ref document: 20111202

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 11846998

Country of ref document: EP

Kind code of ref document: A2